

Efficient ibuprofen delivery from silicone-cellulose topical formulation

Combining the characteristics of silicone and cellulose to find commercially viable hydro-alcoholic topical gel platform to deliver drugs efficiently



Synopsis

A commercially viable hydro-alcoholic topical gel formulation, incorporated with DuPont's silicone and cellulose technologies, containing 5% ibuprofen delivered ~7X drug compared to commercial benchmark. Formulation was physically stable, showed no drug crystal formation and showed 97% drug recovery after exposed to 60°C/30% RH for 4 weeks. Formulation is nearly clear and aesthetically pleasant.


Formulation

Made with polydimethylsiloxane (PDMS, 12,500 cSt), hydroxypropylmethylcellulose (HPMC, Methocel™ K4100), propylene glycol, oleyl alcohol, isopropyl alcohol (IPA), and water; No physical separation when centrifuged; Nearly clear and aesthetically pleasant.

Formulation features


- All FDA-IID listed ingredients
- Hydro-alcoholic gel
- 30% or more water
- Commercial viability
- 7X drug delivery vs commercial benchmark
- Drug delivery for 8 hr or more
- 97% drug recovery after 4 weeks at 60°C/30% RH
- Nearly clear and aesthetically pleasant

Drug delivery profile



In-vitro permeability experiments at 32°C for 8 hr; cadaver epidermis as membrane; phosphate buffered saline (pH 7.4) as receptor fluid; formulations (A,B&C) differ by solvent amount; formulations and commercial benchmark contain 5% ibuprofen.


Inhibition of drug crystal formation




Formulation prepared only with PDMS, HPMC, IPA, water and ibuprofen to demonstrate the effect of HPMC on crystal inhibition; images captured at 100X with plane polarized light.

Technology synergy & benefits


- Assists for efficient drug delivery via concentration gradient
- Provides aesthetics



- Thickens formulation
- Inhibits drug crystallization
- Supports to add high level of liquid ingredients



Drug stability at 60°C/30% RH



Normalized % ibuprofen recovery when formulation_A was exposed to accelerated thermal conditions for 4 weeks.



To learn more about DuPont's healthcare solutions visit:
www.dupont.com/healthcare.html

For country-level information, visit:
www.dupont.com/corporate-functions/our-company/global-locations.html



CAUTION: DO NOT USE DUPONT MATERIALS IN MEDICAL APPLICATIONS INVOLVING PERMANENT IMPLANTATION IN THE HUMAN BODY OR PERMANENT CONTACT WITH INTERNAL BODILY FLUIDS OR TISSUES. DO NOT USE DUPONT MATERIALS IN MEDICAL APPLICATIONS INVOLVING BRIEF OR TEMPORARY IMPLANTATION IN THE HUMAN BODY OR PERMANENT CONTACT WITH INTERNAL BODILY FLUIDS OR TISSUES UNLESS THE MATERIAL HAS BEEN PROVIDED DIRECTLY BY DUPONT UNDER A CONTRACT THAT EXPRESSLY ACKNOWLEDGES THE CONTEMPLATED USE.

The information, suggestions and data contained herein are intended only as an informational guide to assist you in making preliminary selections of materials and are not intended to be all-inclusive or final. Because DuPont cannot anticipate or control the many different conditions under which this information, data, suggestions or materials may be used, DuPont does not guarantee the applicability or the accuracy of this information or the suitability of the information, data, suggestions, or materials in any given situation. The information, data, or suggestions are not intended to substitute for any testing you may need to conduct to determine for yourself the suitability of a particular material for a particular purpose. DuPont makes no guarantee of results and assumes no obligation or liability whatsoever in connection with this information. Such information, data or suggestions are to be used and relied upon at user's own discretion and risk. DuPont makes no warranties, express or implied, and disclaims any and all direct and indirect liability for damages or losses resulting from or relating to the use of any information, suggestion, data, or materials described herein. Statements concerning the use of the products or formulations described herein are not to be construed as recommending the infringement of any patent, copyright, designs or other intellectual property and no liability for infringement arising out of such use is assumed by DuPont. None of this information is to be considered as a license to operate under, or recommendation to infringe, any patents.

DuPont reserves the right not to sell Special Control and Premium Control products for selected applications.

Although these products are tested against certain USP Class VI and ISO 10993 standards, DuPont makes no representation or warranty of suitability of its products for particular healthcare or medical applications or any other representations or warranties based on such testing.

The information set forth herein is furnished free of charge and is based on technical data that DuPont believes to be reliable. It is intended for use by persons having technical skill at their own discretion and risk. DuPont makes no warranties, express or implied, and assumes no liability in connection with any use of this information.

DuPont™, the DuPont Oval Logo, and all products, unless otherwise noted, denoted with ™, SM or © are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

© 2020 DuPont de Nemours, Inc. All rights reserved.

Form Number: 001-20400-CDP0820